Division of Wockhardt Ltd.
Latest From Negma Laboratories
Dr Habil Khorakiwala, Wockhardt’s chair and group CEO, recounts his life and business journey, including an acquisition that went wrong, in an interview with Scrip as part of our ongoing executive profile series. Khorakiwala also outlines where he sees Wockhardt in the coming years, with the firm’s R&D thrust in the antibiotics space expected to play a pivotal role.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.